Hideki Katayama

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Lung Neoplasms 98%
3. Gefitinib 95%
4. Cisplatin 85%
5. Observational Studies 73%
6. Cyclooxygenase 2 Inhibitors 66%
7. Methylation 65%
8. Celecoxib 65%
9. Neoplasms 65%
10. Adrenal Cortex Hormones 61%
11. Carcinogenesis 60%
12. Prospective Studies 60%
13. erbB-1 Genes 54%
14. Malignant Mesothelioma 53%
15. Dyspnea 52%
16. Lung 51%
17. Malignant Pleural Effusion 41%
18. Anorexia 39%
19. Death-Associated Protein Kinases 37%
20. Retinoic Acid Receptors 36%
21. polyphenon E 36%
22. Polymerase Chain Reaction 34%
23. Mutation 33%
24. Odds Ratio 32%
25. DNA 32%
26. Drug Therapy 31%
27. ErbB Receptors 30%
28. Delirium 29%
29. 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone 29%
30. Pure Red-Cell Aplasia 28%
31. Advance Care Planning 26%
32. Hemoperfusion 26%
33. Methyltransferases 26%
34. Survival 26%
35. Fatigue 25%
36. Nitrosamines 25%
37. Autoimmune Haemolytic Anaemia 25%
38. Drug Hypersensitivity 25%
39. Peripheral Blood Stem Cell Transplantation 25%
40. Polymyxin B 25%
41. DNA Repair 24%
42. Tumor Suppressor Genes 24%
43. epigallocatechin gallate 24%
44. Insulin-Like Growth Factor Binding Protein 3 23%
45. DNA Methylation 23%
46. Idiopathic Pulmonary Fibrosis 22%
47. Phosphopyruvate Hydratase 22%
48. Xenopus laevis 22%
49. Lymphoma, Large B-Cell, Diffuse 21%
50. Docetaxel 21%